Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
$0.01
-38.8%
$0.01
$0.00
$0.01
$13.75M-2.342,654 shs246,000 shs
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.86
+14.1%
$1.51
$1.10
$16.10
$114.18M1.43865,742 shs3.43 million shs
XBiotech Inc. stock logo
XBIT
XBiotech
$2.92
-2.0%
$3.04
$2.50
$8.32
$89.02M0.8546,738 shs30,295 shs
Zomedica Corp. stock logo
ZOM
Zomedica
$0.12
$0.09
$0.16
$95.35M1.034.72 million shs790,936 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
-38.82%-38.82%-37.35%+4.00%+79.31%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
+14.11%+13.41%+10.06%+14.11%-85.49%
XBiotech Inc. stock logo
XBIT
XBiotech
-2.01%-7.59%+0.69%+0.69%-48.95%
Zomedica Corp. stock logo
ZOM
Zomedica
0.00%0.00%0.00%0.00%-24.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
$0.01
-38.8%
$0.01
$0.00
$0.01
$13.75M-2.342,654 shs246,000 shs
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.86
+14.1%
$1.51
$1.10
$16.10
$114.18M1.43865,742 shs3.43 million shs
XBiotech Inc. stock logo
XBIT
XBiotech
$2.92
-2.0%
$3.04
$2.50
$8.32
$89.02M0.8546,738 shs30,295 shs
Zomedica Corp. stock logo
ZOM
Zomedica
$0.12
$0.09
$0.16
$95.35M1.034.72 million shs790,936 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
-38.82%-38.82%-37.35%+4.00%+79.31%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
+14.11%+13.41%+10.06%+14.11%-85.49%
XBiotech Inc. stock logo
XBIT
XBiotech
-2.01%-7.59%+0.69%+0.69%-48.95%
Zomedica Corp. stock logo
ZOM
Zomedica
0.00%0.00%0.00%0.00%-24.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
0.00
N/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
2.08
Hold$8.19340.19% Upside
XBiotech Inc. stock logo
XBIT
XBiotech
0.00
N/AN/AN/A
Zomedica Corp. stock logo
ZOM
Zomedica
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

Latest LTUS, XBIT, PLRX, and ZOM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/10/2025
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
8/8/2025
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$17.00 ➝ $4.00
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.58M72.27N/AN/A$5.00 per share0.37
XBiotech Inc. stock logo
XBIT
XBiotech
$4.01M22.20N/AN/A$5.98 per share0.49
Zomedica Corp. stock logo
ZOM
Zomedica
$25.19M0.00N/AN/A$0.24 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
$110KN/A0.00N/AN/AN/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$210.30M-$3.40N/AN/AN/AN/A-73.45%-55.66%11/6/2025 (Estimated)
XBiotech Inc. stock logo
XBIT
XBiotech
-$38.53M-$0.92N/AN/AN/A-15.60%-14.64%11/11/2025 (Estimated)
Zomedica Corp. stock logo
ZOM
Zomedica
-$34.53M-$0.06N/AN/AN/A-232.88%-12.47%-11.84%N/A

Latest LTUS, XBIT, PLRX, and ZOM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
XBiotech Inc. stock logo
XBIT
XBiotech
N/A-$0.06N/A-$0.06N/AN/A
8/7/2025Q2 2025
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$0.62-$0.71-$0.09-$0.71N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/AN/AN/AN/AN/A
XBiotech Inc. stock logo
XBIT
XBiotech
N/AN/AN/AN/AN/A
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
0.14
12.99
12.99
XBiotech Inc. stock logo
XBIT
XBiotech
N/A
40.16
40.16
Zomedica Corp. stock logo
ZOM
Zomedica
N/A
10.82
10.15

Institutional Ownership

CompanyInstitutional Ownership
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
97.30%
XBiotech Inc. stock logo
XBIT
XBiotech
55.70%
Zomedica Corp. stock logo
ZOM
Zomedica
8.95%

Insider Ownership

CompanyInsider Ownership
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
8.00%
XBiotech Inc. stock logo
XBIT
XBiotech
30.80%
Zomedica Corp. stock logo
ZOM
Zomedica
4.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lotus Pharmaceuticals Inc. stock logo
LTUS
Lotus Pharmaceuticals
2302.64 billionN/ANot Optionable
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
9061.39 million56.48 millionOptionable
XBiotech Inc. stock logo
XBIT
XBiotech
10030.49 million21.10 millionOptionable
Zomedica Corp. stock logo
ZOM
Zomedica
50979.95 million938.89 millionNot Optionable

Recent News About These Companies

15 Cheapest Stocks Insiders Are Buying In March
Q4 2024 Zomedica Corp Earnings Call
Zomedica Corp. (ZOMDF) Q4 2024 Earnings Call Transcript
Zomedica (ZOMDF) Gets a Buy from Noble Financial
Zomedica Corp.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lotus Pharmaceuticals stock logo

Lotus Pharmaceuticals OTCMKTS:LTUS

$0.0052 0.00 (-38.82%)
As of 09/5/2025 12:45 PM Eastern

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.

Pliant Therapeutics stock logo

Pliant Therapeutics NASDAQ:PLRX

$1.86 +0.23 (+14.11%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$1.81 -0.05 (-2.69%)
As of 09/5/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

XBiotech stock logo

XBiotech NASDAQ:XBIT

$2.92 -0.06 (-2.01%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$2.92 0.00 (0.00%)
As of 09/5/2025 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Zomedica stock logo

Zomedica NYSEAMERICAN:ZOM

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.